John Kerr posted in cancer • drug funding • keytruda • melanoma • pembrolizumab • pharmac on December 3rd, 2015.
PHARMAC’s decision not to fund melanoma treatment pembrolizumab – marketed as Keytruda – has been widely covered in the media. Public pressure to fund the drug increased in September this year following coverage of impressive recoveries attributed to the treatment, and registration of the drug with MedSafe. However according to PHARMAC’s analysis of the available evidence, […]
Continue reading “PHARMAC not to fund melanoma drug – In the News”